|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100053502 |
|
最近更新日期: Date of Last Refreshed on: |
2022-05-15 08:32:13 |
|
注册时间: Date of Registration: |
2021-11-23 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
个体化营养干预改善妊娠高血压疾病高风险孕妇母婴结局的前瞻性随机对照研究 |
|
Public title: |
Prospective randomized controlled study of individualized nutritional intervention to improve maternal and infant outcomes in pregnant women at high risk of pregnancy hypertension |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
个体化营养干预改善妊娠高血压疾病高风险孕妇母婴结局的前瞻性随机对照研究 |
|
Scientific title: |
Prospective randomized controlled study of individualized nutritional intervention to improve maternal and infant outcomes in pregnant women at high risk of pregnancy hypertension |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郑秀惠 |
研究负责人: |
郑秀惠 |
|
Applicant: |
Zheng Xiuhui |
Study leader: |
Zheng Xiuhui |
|
申请注册联系人电话: Applicant telephone: |
+86 15823495993 |
研究负责人电话: Study leader's telephone: |
+86 15823495993 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lph1972@163.com |
研究负责人电子邮件: Study leader's E-mail: |
lph1972@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市渝中区大坪长江之路10号 |
研究负责人通讯地址: |
重庆市渝中区大坪长江之路10号 |
|
Applicant address: |
10 Changjiang Branch Road, Daping, Yuzhong District, Chongqing |
Study leader's address: |
10 Changjiang Branch Road, Daping, Yuzhong District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
陆军特色医学中心 |
||
|
Applicant's institution: |
Army Specialized Medical Center |
||
|
研究负责人所在单位: |
陆军特色医学中心 |
||
|
Affiliation of the Leader: |
Army Specialized Medical Center |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
医研伦审(2021)第136号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军特色医学中心伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of PLA Army Specialized Medical Center |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-09-14 00:00:00 |
||
|
伦理委员会联系人: |
范士志 |
||
|
Contact Name of the ethic committee: |
Fan Shizhi |
||
|
伦理委员会联系地址: |
重庆市渝中区大坪长江之路10号 |
||
|
Contact Address of the ethic committee: |
10 Changjiang Branch Road, Daping, Yuzhong District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
陆军特色医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
Army Specialized Medical Center |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市渝中区大坪长江之路10号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
10 Changjiang Branch Road, Daping, Yuzhong District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
医学科研项目(非中医药类)重点项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Key project of Medical research projects (Non-traditional Chinese medicine) |
||||||||||||||||||||||
|
Target disease: |
hypertensive disorder of pregnancy |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
⑴通过测量孕妇体成分、sFlt-1/PLGF、尿靛甙化验定量检测等,制定个性化营养食谱,从而能够对孕妇进行科学合理的营养指导,良好控制体重、血压、血糖、血色素、血脂等指标。 ⑵通过分析比较两组孕妇妊娠分娩期及其胎婴儿的健康状况、合并疾病、巨大儿、出生缺陷等发生率,评价不同营养干预措施产生的影响,进一步证实孕期营养监测和指导对改善妊娠期高血压疾病高风险孕妇母儿结局的重要性。 |
||||||||||||||||||||||
|
Objectives of Study: |
1)Through the measurement of body composition, SFLT-1 /PLGF, indigoside assay and quantitative detection of pregnant women, personalized nutritional diet can be developed, so as to provide scientific and reasonable nutritional guidance for pregnant women, and good control of weight, blood pressure, blood glucose, hemoglobin, blood lipid and other indicators 2)Through the analysis and comparison of the two groups of pregnant women during pregnancy and the health status of their babies, complications, macrosomia, birth defects and other incidence rates,to evaluate the impact of different nutritional interventions to further confirm the importance of nutrition monitoring and guidance during pregnancy to improve maternal and neonatal outcomes in women at high risk of hypertensive disorders during pregnancy. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
单胎妊娠 6-13+6周在我院建卡产检的孕妇,第一次产前检查时运用 Mp 妊娠高血压综合征监测系统筛查出妊娠高血压疾病高风险者,或风险低但具备以下高危因素之一者:孕妇年龄≥40 岁、子痫前期病史、抗磷脂抗体阳性、高血压(未造成器质损害)、慢性肾炎(此次妊娠肾功能正常)、糖尿病或遗传性血栓形成倾向、初次产检时 BMI≥35kg/m2、子痫前期家族史(母亲或者姐妹)、首次怀孕、妊娠间隔时间≥10 年以及早孕期收缩压≥130mmHg 或舒张压≥80mmHg。 |
||||||||||||||||||||||
|
Inclusion criteria |
Among the pregnant women with single pregnancy at 6-13+6 weeks, the Mp gestational hypertension syndrome monitoring system was used to screen the high-risk gestational hypertension disease during the first prenatal examination.Or low risk but with one of the following risk factors:Age ≥40 years, history of preeclampsia, positive antiphospholipid antibodies, hypertension (no organ damage), chronic nephritis (normal renal function during this pregnancy), diabetes or genetic propensity for thrombosis, BMI≥35kg/m2 at the first prenatal examination, family history of preeclampsia (mother or sister), first pregnancy, pregnancy interval ≥10 years or Systolic blood pressure ≥130mmHg or diastolic blood pressure ≥80mmHg in early pregnancy. |
||||||||||||||||||||||
|
排除标准: |
有早产史,有死胎史,有胎儿生长受限、低出生体重儿史,有产后出血、胎盘早剥史,有严重心脑血管、内分泌、血液系统疾病史。脱落标准:此次妊娠为前置胎盘、胎盘植入、胎儿致死性畸形者。正在参与其他临床研究者;拒绝参加本研究者,或同意参加本研究,但拒绝签署知情同意书者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Exclusion criteria: history of preterm birth, stillbirth, fetal growth restriction, low birth weight, postpartum hemorrhage, placental abruption, and serious cardio-cerebrovascular, endocrine, and hematological diseases.Shedding criteria: this pregnancy is placenta previa, placenta accreta, fetal fatal malformation.Participating with other clinical investigators;Refuse to participate in the study, or agree to participate in the study but refuse to sign the informed consent. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-11-01 00:00:00至 To 2024-12-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2021-12-01 00:00:00 至 To 2023-12-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
患者编号:每位孕妇依据门诊建卡先后进行编号。 随机分组:同一时段内孕妇根据随机表进入综合营养干预组或对照组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patient number: Each pregnant woman was numbered according to the first prenatal examination. Randomized grouping: Pregnant women were assigned to the comprehensive nutrition intervention group or control group according to the random table during the same period. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
no |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
no |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |